TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06497764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrational Anesthesia (VA) Device
Description: The half of the patient's scalp randomized to receive VA during PRP treatment will receive VA via the Buzzy bee-striped personal. The device is powered by two AAA batteries and is indicated for use for pain reduction. It uses the Melzack and Wall's Gait Control theory, which states that activation of non-nociceptive fibers can interfere with signals from pain fibers to inhibit overall sensation of pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrational Anesthesia (VA) Device
Description: The half of the patient's scalp randomized to receive VA during PRP treatment will receive VA via the Buzzy bee-striped personal. The device is powered by two AAA batteries and is indicated for use for pain reduction. It uses the Melzack and Wall's Gait Control theory, which states that activation of non-nociceptive fibers can interfere with signals from pain fibers to inhibit overall sensation of pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP Treatment
Description: PRP (a needle-related procedure) will be delivered per routine standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP Treatment
Description: PRP (a needle-related procedure) will be delivered per routine standard of care.
Study: NCT05750732

Intervention type: BEHAVIORAL
Intervention: Weight loss diet
Description: Participants in the study group will be given training on the weight loss diet, which is a routine part of their treatment.
Study: NCT05900336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Naproxen
Description: One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Naproxen
Description: One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
Study: NCT06295991

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lycra garment
Description: Investigation of the effect on balance and respiratory functions by using specially produced lycra garments for 6 hours a day for 16 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lycra garment
Description: Investigation of the effect on balance and respiratory functions by using specially produced lycra garments for 6 hours a day for 16 weeks
Study: NCT06166043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION
Description: An online training consisting of 10 sessions in total for 5 weeks will be given to the patients in order to improve their fatigue management skills. In addition to this training, they will receive a nurse support program.
Study: NCT05069311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Description: Multimodal analgesia includes the combination of:~1. morphine given by PCA (patient-controlled analgesia) at 1 mg/dose~2. bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively~3. bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively~4. bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour~5. etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery~6. paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional intravenous analgesia
Description: Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
Study: NCT05463237

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes
Study: NCT05062330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution administered 7 times over two consecutive days
Study: NCT05275751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPA1-inhibitor
Description: Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPA1-inhibitor
Description: Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPA1-inhibitor
Description: Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPA1-inhibitor
Description: Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPA1-inhibitor
Description: Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV1-inhibitor
Description: Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV1-inhibitor
Description: Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV1-inhibitor
Description: Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV1-inhibitor
Description: Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV1-inhibitor
Description: Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV1-inhibitor
Description: Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV1-inhibitor
Description: Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV1-inhibitor
Description: Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPM3-inhibitor
Description: Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPM3-inhibitor
Description: Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid
Study: NCT06462612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally, once daily
Study: NCT06447298

Intervention type: OTHER
Intervention: Satisfaction questionnaires
Description: Use of a post-laparoscopy satisfaction questionnaire designed to be adapted to the context of laparoscopic surgery. This post-laparoscopy questionnaire was inspired by the PedsQL generic care satisfaction questionnaire, a standardised and validated questionnaire.
Study: NCT06570434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budoprutug
Description: monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budoprutug
Description: monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budoprutug
Description: monoclonal antibody
Study: NCT06207084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asynchronous content only
Description: Receives asynchronous exercise content and no live training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asynchronous content and health coaching and no live training
Description: Receives asynchronous content, health coaching and no live training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asynchronous content only and 1 on 1 live training
Description: receives asynchronous content and live 1 on 1 training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asynchronous content and health coaching and 1 on 1 training
Description: receives asynchronous content, health coaching, and live training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asynchronous content and group training
Description: receives asynchronous content and live group training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asynchronous content and health coaching and group training
Description: receives asynchronous content, health coaching, and live group training
Study: NCT06646601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention of prevention
Description: A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops.
Study: NCT06647186

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non Incised Papillae Surgical Approach
Description: Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. A single horizontal or oblique incision was made in the mucosa located on the cortical bone tissue, apical to the intrabony defect. The mesiodistal extension of the incision was sufficient to allow access to the defect. Tissue coronal to the incision was raised to full thickness from the incision line to expose the bone peaks delimiting the intrabony defect. The granulation tissue was removed from the bone walls of the defect. Dental plaque and calculus deposits were removed from the root surface with ultrasonic scaler tips and micro-minicurettes. A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with horizontal internal mattress sutures then simple interrupted sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional flap design
Description: Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. Intrasulcular incision was made splitting the buccal papilla from the palatal papilla. All defects were approached by elevating a flap only on the buccal side and leaving the oral portion of the interdental supracrestal soft tissues undetached. The full-thickness elevation of the marginal portion of the flap was performed with a microsurgical periosteal elevator.~After removal of granulation tissue from the bone walls of the defect, root and defect debridement was performed with manual and mechanical (ultrasonic) instruments with tips for subgingival instrumentation.~A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with simple interrupted sutures.
Study: NCT06646744

Intervention type: BIOLOGICAL
Intervention: mRNA COVID-19 vaccine
Description: Children will be vaccinated according to standard local procedure
Study: NCT05255276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitravatinib 50 mg
Description: 50 mg Sitravatinib on Day 1 (Group 1A)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitravatinib 100 mg
Description: 100 mg Sitravatinib on Day 1 (Group 2A)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)
Study: NCT06012955

Intervention type: DEVICE
Intervention: Target-controlled infusion (TCI) systems
Description: Target-controlled infusion (TCI) with propofol and remifentanil was used for anesthesia induction and maintenance
Study: NCT05845450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: trastuzumab deruxtecan 5.4 mg/kg IV on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 1500 mg IV on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: panitumumab 6 mg/kg IV on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: panitumumab 6 mg/kg IV on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: botensilimab 1 mg/kg on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: botensilimab 1 mg/kg on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: botensilimab 1 mg/kg on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: botensilimab 1 mg/kg on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: balstilimab 3 mg/Kg on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: balstilimab 3 mg/Kg on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: sotorasib 960 mg orally once daily from day 1 to 28
Study: NCT05080283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1110 Sound Processor System
Description: Sound Processor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1110 Sound Processor System
Description: Sound Processor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nucleus 7 Sound Processor (model: CP1000) system
Description: Sound Processor
Study: NCT05528913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasenra Prefilled Syringe
Description: Fasenra 60mg s.c. administration at weeks 0,4 and 8

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Solution
Description: Placebo s.c. administration at weeks 0,4 and 8
Study: NCT04439019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle and dietary modification program
Description: The OA Optimization Program is a lifestyle and dietary modification program. All Patients will be offered this optional program while they await orthopedic consultation. There is an initial group information session for participants followed by medical assessment which includes medical history and physical examination, a previous dietary history, a readiness for change assessment, and screening for contraindications to the program. The patients will then attend group counselling sessions every 3 months for 1 year, or until their surgical date.Patients are encouraged to attend sessions with a family member. Improvement in Quality of Life measures including pain and disability in patients with severe osteoarthritis, as well as improvements in markers of health such as BMI, waist circumference, blood pressure, medication use in diabetic and hypertensive patients, and markers such as serum lipids and markers of inflammation will be shown.
Study: NCT05320107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% NaCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% NaCl
Study: NCT05275751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPM3-inhibitor
Description: Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPM3-inhibitor
Description: Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPM3-inhibitor
Description: Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPM3-inhibitor
Description: Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPM3-inhibitor
Description: Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPM3-inhibitor
Description: Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No pharmacological intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloride-channel inhibitor
Description: Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloride-channel inhibitor
Description: Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloride-channel inhibitor
Description: Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloride-channel inhibitor
Description: Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloride-channel inhibitor
Description: Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloride-channel inhibitor
Description: Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloride-channel inhibitor
Description: Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloride-channel inhibitor
Description: Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid
Study: NCT05689814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paraffin based Denture Fixative
Description: Denture fixative applied in strips to secure dentures in place

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin based Denture Fixative
Description: Denture fixative applied in strips to secure dentures in place
Study: NCT04924764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy.
Description: Conventionally used intervention for subacute and chronic neck pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy.
Description: Conventionally used intervention for subacute and chronic neck pain.
Study: NCT05923593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAG oil oral nutritional supplement (ONS)
Description: The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil.
Study: NCT03354520

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Videos
Description: web-based OSA messages (videos featuring role models and coaching advice using motivational enhancement) addressing OSA barriers within a health literacy framework--to decrease cognitive load and render messages understandable and actionable. OSA messages were tailored based on focus group data in the previous study (group tailoring).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OSA Treatment
Description: Web-based platform delivering messages promoting OSA self-efficacy. . All patients will view the introductory video, followed by the video cluster: Sleep, Health, and Well-Being; Sleep-Heart Health; Lifestyle Changes; and Sleep Hygiene.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Videos
Description: Patients in the control arm will also receive an iPad, providing access to standard online OSA health information (e.g., National Sleep Foundation) in an equivalent dose as in the intervention arm using pre-selected automatic alerts to access the website